The three approved claims are: helps support prostate health; clinically shown to support prostate health; and helps to relieve the urologic symptoms associated with benign prostatic Hyperplasia.
“Receiving these health claims from Health Canada bolsters our research in prostate health with AGEprost by being able to offer a viable solution for those suffering with prostate disorders,” Chase Shryoc, Gencor’s vice president of sales and business development, said. “We’re proud to promote these approved claims by Health Canada because of their stringent requirements and standards in allowance to any claim.”
A 12-week double-blind, randomized, placebo-controlled study, published in the journal BioFactors, was conducted on 109 men between the ages of 41 and 76. In the active group, there was a steady reduction in the symptom severity for all questions in the International Prostate Symptom Score (IPSS), and a decrease in both daytime and nighttime frequency with significant reduction in total urinary frequency.
As a 5-a-reductase inhibitor, AGEprost has shown the ability to relax muscles around the urethra and smooth muscles of the neck of the bladder helping relieve urinary retention and frequency. It can also block conversion of testosterone to DHT with subsequent reduction in prostate size improving urine flow, the authors of the study said.
“AGEprost is part of Gencor’s Healthy Aging portfolio of ingredients for men, each of which are backed by scientific studies and extensive clinical research,” Srhyoc said. “AGEprost has proven itself to be a beneficial ingredient for aging men.”